Orexo, AstraZeneca deal

Orexo granted AstraZeneca rights to conduct further preclinical research of compounds in Orexo's OX-CLI program, which comprises compounds that inhibit leukotriene C4 synthase (LTC4S) in preclinical development for respiratory diseases. The pharma also has a three-year option to acquire exclusive, worldwide rights to compounds from the program for all indications. Orexo received an undisclosed upfront payment. If AstraZeneca exercises the option, Orexo will also be eligible for undisclosed milestones, plus royalties. The companies declined to provide details. ...